Evaluating biomarkers in fatty liver disease in Nordic countries
Fatty Liver Disease in Nordic Countries (FLINC): a Prospective Cohort Study
This study is trying to find out if certain biological markers can help improve the understanding and treatment of fatty liver disease in people with and without the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 634 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Copenhagen University Hospital, Hvidovre Academic / other |
| Locations | 1 site (Hvidovre, Capital Region Denmark) |
| Trial ID | NCT04340817 on ClinicalTrials.gov |
What this trial studies
This observational study aims to systematically evaluate biomarkers and potential therapeutic targets in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). It involves a prospective cohort design, where both individuals diagnosed with NAFLD and healthy volunteers will be assessed. The study will utilize advanced techniques such as proteomics, transcriptomics, and genomics to gather comprehensive data on the disease. The findings could lead to better understanding and management of fatty liver disease.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Non-Alcoholic Fatty Liver Disease as well as healthy volunteers for comparison.
Not a fit: Patients with other liver diseases or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that lead to improved diagnostic and therapeutic strategies for patients with fatty liver disease.
How similar studies have performed: While there have been studies focusing on biomarkers in fatty liver disease, this specific approach utilizing a cohort design and advanced omics technologies may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-alcoholic fatty liver disease and * Healthy volunteers Exclusion Criteria: * Other liver diseases than non-alcoholic fatty liver disease * Lack of informed consent
Where this trial is running
Hvidovre, Capital Region Denmark
- Gastrounit, Copenhagen University Hospital Hvidovre — Hvidovre, Capital Region Denmark, Denmark (Recruiting)
Study contacts
- Principal investigator: Lise L Gluud, MD — Copenhagen University Hospital, Hvidovre
- Study coordinator: Lise L Gluud, MD
- Email: lise.lotte.gluud.01@regionh.dk
- Phone: +45 38623862
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.